I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised thyroglobulin, Tg

Míreanna comhchosúla

• The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
  de réir: Ali, N, et al.
  Foilsithe / Cruthaithe: (2006)
• The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
  de réir: Siddiqi, A, et al.
  Foilsithe / Cruthaithe: (2001)
• Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
  de réir: Mukherjee, J, et al.
  Foilsithe / Cruthaithe: (2001)
• NMR-ON MEASUREMENTS OF I-123, I-124, I-131 IN NICKEL
  de réir: Ohya, S, et al.
  Foilsithe / Cruthaithe: (1992)
• Prevalence of Thyroglobulin Antibody (TgAb) positivity in patients post treatment for differentiated thyroid carcinoma and verification of serum thyroglobulin measurements by thyroglobulin recovery test and TgAb assay
  de réir: Kathiravelu, Kaameny, et al.
  Foilsithe / Cruthaithe: (2022)